₹4999
(Inclusive of all Taxes)
Get Free delivery (₹99) with



Composition :
Manufacturer/Marketer :
Consume Type :
Expires on or after :
Return Policy :
About Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml
Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml is an antidiabetic medicine used to improve blood sugar control in adults with type 2 diabetes when diet, exercise, or other medicines are not enough. Type 2 diabetes occurs when the body does not produce enough insulin or cannot use it effectively.
Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml contains semaglutide, which works by releasing insulin when blood sugar is high, reducing sugar production in the liver, and slowing stomach emptying. It is used along with diet and exercise to help maintain steady blood sugar levels.
Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml should be administered by a healthcare professional or used only after proper training. Common side effects may include nausea, vomiting, diarrhoea, stomach pain, and constipation, which usually improve over time.
Inform your doctor if you have any allergies or medical conditions, or if you are taking other medicines. Avoid use if you or your family has a history of medullary thyroid cancer (MTC) or MEN 2. Do not use during pregnancy, breastfeeding, or in children under 12 years, and stop at least 2 months before a planned pregnancy.
Uses of Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml
Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml injection is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes.

Have a query?
Directions for Use
Key Benefits
Effective Blood Sugar Management: 0.25 mg / 0.5 mg Prefilled Pen: Designed for treatment initiation, these lower doses help the body gradually adjust to semaglutide while starting blood sugar control.
Advanced Glycemic Control: 1 mg Prefilled Pen: A higher-dose maintenance option for patients needing stronger and sustained blood sugar control after initial treatment phases.
How Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml Works
Storage
What if I have taken an overdose of Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml
Drug Warnings
Diet & Lifestyle Advise
Habit Forming
Therapeutic Class
RXAlkem Laboratories Ltd
₹1900
(₹1900.0 per unit)
Alcohol
Caution
You are recommended to avoid alcohol consumption while taking Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml. It could lead to increased adverse events.
Pregnancy
Unsafe
Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml should not be used during pregnancy as there is a potential risk of harm to the unborn baby. Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml is not recommended for women who are pregnant, planning to conceive soon, or not using reliable contraception during therapy. Additionally, it must be discontinued at least 2 months before a planned pregnancy because of its long washout period.
Breast Feeding
Caution
Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml is not recommended during breastfeeding as its safety is not established.
Driving
Caution
Generally does not impair ability to drive; however, dizziness or low blood sugar (if combined with other drugs) may affect alertness.
Liver
Caution
Inform your doctor before receiving Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml if you have a pre-existing or a history of liver disease. Your doctor will prescribe only if the benefits outweigh the risks.
Kidney
Caution
Inform your doctor before receiving Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml if you have a pre-existing or a history of kidney disease. Your doctor will prescribe only if the benefits outweigh the risks.
Children
Unsafe
Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml is not recommended for children as efficacy and safety have not been established.
Heart
Caution
Inform your doctor if you have any heart conditions before using Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml. The doctor will prescribe it only if the potential benefits outweigh the risks.
Geriatrics
Caution
Older adults may be more sensitive to the effects of Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml. The dose and treatment plan should be carefully determined by a doctor, taking into account overall health, kidney function, and other medications. Regular monitoring is recommended to ensure safety and effectiveness.
Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml contains semaglutide, an antidiabetic medication that helps lower blood sugar in adults with type 2 diabetes. It works by stimulating insulin release only when blood sugar is high, reducing the amount of sugar your liver produces, and slowing the emptying of food from your stomach. These actions help keep blood sugar steadier throughout the day and after meals. Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml is usually used alongside diet and exercise to support overall diabetes management.
Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml is used alongside diet and exercise to improve blood sugar (glycemic) control in adults with type 2 diabetes mellitus.
Common side effects include nausea, vomiting, diarrhoea, abdominal pain, and constipation. Rare but serious risks include pancreatitis, diabetic eye complications, kidney problems, gallbladder disease, and severe allergic reactions.
Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml is not suitable for every adult with type 2 diabetes. It is prescribed only when a doctor determines it is appropriate based on the patient’s medical history, current health status, and treatment goals. It should never be used without medical supervision, as self-administration can lead to serious complications.
Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml is administered as a subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. The dose and frequency are determined by a doctor based on your treatment stage, blood sugar targets, and overall health. Self‑administration without medical guidance is not recommended, as incorrect use can lead to serious complications.
No, Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml is not safe or appropriate for people with type 1 diabetes. Semaglutide (Poviztra 0.5 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml) is only approved for type 2 diabetes.
Country of origin
Manufacturer/Marketer address
Keep Refrigerated. Do not freeze.Prepaid payment required.
We provide you with authentic, trustworthy and relevant information